U.S. markets closed

WuXi AppTec Co., Ltd. (WUXAY)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
19.950.00 (0.00%)
At close: 9:32AM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close19.95
Open19.95
BidN/A x N/A
AskN/A x N/A
Day's Range19.95 - 19.95
52 Week Range19.95 - 22.40
Volume1
Avg. Volume207
Market Cap51.89B
Beta (5Y Monthly)0.87
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • PR Newswire

    WuXi AppTec Reports Strong 2020 Annual Results

    WuXi AppTec (stock code: 603259.SH / 2359.HK), a company that provides a broad portfolio of R&D and manufacturing services that enable companies in the pharmaceutical, biotech and medical device industries worldwide to advance discoveries and deliver groundbreaking treatments to patients, announces its audited annual results for the year ended December 31, 2020 ("Reporting Period").

  • WuXi AppTec Completes Acquisition of OXGENE to Further Strengthen Cell and Gene Therapy Service Offerings for Global Customers
    PR Newswire

    WuXi AppTec Completes Acquisition of OXGENE to Further Strengthen Cell and Gene Therapy Service Offerings for Global Customers

    WuXi AppTec, a leading global provider of R&D- and manufacturing-enabling services in the pharmaceutical, biotechnology and medical device industries, today announced that it has completed the acquisition of OXGENE, a pioneering United Kingdom-based contract research and development organization that designs and develops scalable gene therapy technologies. This acquisition enables WuXi AppTec to offer its customers end-to-end support in the creation and development of cutting-edge cell and gene therapies for patients in need worldwide.

  • WuXi AppTec Recognized by Frost & Sullivan with 2020 Global Customer Value Leadership Award
    PR Newswire

    WuXi AppTec Recognized by Frost & Sullivan with 2020 Global Customer Value Leadership Award

    WuXi AppTec, a leading global provider of R&D and manufacturing enabling services in the pharmaceutical, biotechnology and medical device industries, today announced that it has received the 2020 Global Customer Value Leadership Award from Frost & Sullivan, a global business research and consulting firm. This marks the fourth consecutive year WuXi AppTec has been recognized by Frost & Sullivan for its leadership and innovative services.